Adaptive Pathways Regulations for Stem Cells: Accelerating Access to Medicine or Deregulating Access to Markets?

Tsung-Ling Lee, Tamra Lysaght

Research output: Contribution to journalArticle

Abstract

In response to calls for faster access to innovative biomedicines, the European Medical Agency ran a two-year pilot program known as the “Adaptive Pathways” (AP) scheme. Under this approach, evidence is gathered and evaluated iteratively for license adaptation to reduce uncertainties rather than in an accumulative phased trial process. With the European Medicines Agency (EMA) aiming to mainstream the AP scheme, the regulatory approach of accelerating the approval process for novel biomedicines is in need of critical evaluation and should be viewed with some caution. Focusing on the recent market authorisation of a stem cell product, we scrutinise the legal and ethical merits of this programme. We draw attention to how the AP scheme will grant conditional marketing approval to medicinal products with limited clinical benefits. In response to the identified weaknesses of the AP scheme, we propose procedural safeguards which are in keeping with the EMA’s public health missions.
Original languageEnglish
JournalSCRIPTed
DOIs
Publication statusPublished - Jun 2017

Fingerprint

Licensure
Marketing
Uncertainty
Stem Cells
Public Health
Medicine

Keywords

  • adaptive pathways
  • stem cell regulations
  • adaptive licensing
  • conditional marketing approval
  • Holoclar
  • EMA

Cite this

@article{c42ae8225a12423e9a70891e82ee0621,
title = "Adaptive Pathways Regulations for Stem Cells: Accelerating Access to Medicine or Deregulating Access to Markets?",
abstract = "In response to calls for faster access to innovative biomedicines, the European Medical Agency ran a two-year pilot program known as the “Adaptive Pathways” (AP) scheme. Under this approach, evidence is gathered and evaluated iteratively for license adaptation to reduce uncertainties rather than in an accumulative phased trial process. With the European Medicines Agency (EMA) aiming to mainstream the AP scheme, the regulatory approach of accelerating the approval process for novel biomedicines is in need of critical evaluation and should be viewed with some caution. Focusing on the recent market authorisation of a stem cell product, we scrutinise the legal and ethical merits of this programme. We draw attention to how the AP scheme will grant conditional marketing approval to medicinal products with limited clinical benefits. In response to the identified weaknesses of the AP scheme, we propose procedural safeguards which are in keeping with the EMA’s public health missions.",
keywords = "adaptive pathways, stem cell regulations, adaptive licensing, conditional marketing approval, Holoclar, EMA",
author = "Tsung-Ling Lee and Tamra Lysaght",
year = "2017",
month = "6",
doi = "10.2966/scrip.140117.81",
language = "English",
journal = "SCRIPTed",
issn = "1744-2567",

}

TY - JOUR

T1 - Adaptive Pathways Regulations for Stem Cells

T2 - Accelerating Access to Medicine or Deregulating Access to Markets?

AU - Lee, Tsung-Ling

AU - Lysaght, Tamra

PY - 2017/6

Y1 - 2017/6

N2 - In response to calls for faster access to innovative biomedicines, the European Medical Agency ran a two-year pilot program known as the “Adaptive Pathways” (AP) scheme. Under this approach, evidence is gathered and evaluated iteratively for license adaptation to reduce uncertainties rather than in an accumulative phased trial process. With the European Medicines Agency (EMA) aiming to mainstream the AP scheme, the regulatory approach of accelerating the approval process for novel biomedicines is in need of critical evaluation and should be viewed with some caution. Focusing on the recent market authorisation of a stem cell product, we scrutinise the legal and ethical merits of this programme. We draw attention to how the AP scheme will grant conditional marketing approval to medicinal products with limited clinical benefits. In response to the identified weaknesses of the AP scheme, we propose procedural safeguards which are in keeping with the EMA’s public health missions.

AB - In response to calls for faster access to innovative biomedicines, the European Medical Agency ran a two-year pilot program known as the “Adaptive Pathways” (AP) scheme. Under this approach, evidence is gathered and evaluated iteratively for license adaptation to reduce uncertainties rather than in an accumulative phased trial process. With the European Medicines Agency (EMA) aiming to mainstream the AP scheme, the regulatory approach of accelerating the approval process for novel biomedicines is in need of critical evaluation and should be viewed with some caution. Focusing on the recent market authorisation of a stem cell product, we scrutinise the legal and ethical merits of this programme. We draw attention to how the AP scheme will grant conditional marketing approval to medicinal products with limited clinical benefits. In response to the identified weaknesses of the AP scheme, we propose procedural safeguards which are in keeping with the EMA’s public health missions.

KW - adaptive pathways

KW - stem cell regulations

KW - adaptive licensing

KW - conditional marketing approval

KW - Holoclar

KW - EMA

UR - https://script-ed.org/article/adaptive-pathways-regulations-for-stem-cells-accelerating-access-to-medicine-or-deregulating-access-to-markets/

U2 - 10.2966/scrip.140117.81

DO - 10.2966/scrip.140117.81

M3 - Article

JO - SCRIPTed

JF - SCRIPTed

SN - 1744-2567

ER -